MX339569B - Nuevos cristales y procesos para elaborar 5-({[2-amino-3-(4-carbam oil-2,6-dimetilfenil)-propionil]-[1-(4-fenil-1h-imidazol-2-il)-et il]-amino}-metil)-2-acido metoxibenzoico. - Google Patents

Nuevos cristales y procesos para elaborar 5-({[2-amino-3-(4-carbam oil-2,6-dimetilfenil)-propionil]-[1-(4-fenil-1h-imidazol-2-il)-et il]-amino}-metil)-2-acido metoxibenzoico.

Info

Publication number
MX339569B
MX339569B MX2010000323A MX2010000323A MX339569B MX 339569 B MX339569 B MX 339569B MX 2010000323 A MX2010000323 A MX 2010000323A MX 2010000323 A MX2010000323 A MX 2010000323A MX 339569 B MX339569 B MX 339569B
Authority
MX
Mexico
Prior art keywords
phenyl
amino
propionyl
carbamoyl
methoxy
Prior art date
Application number
MX2010000323A
Other languages
English (en)
Inventor
Luigi Anzalone
Penina Feibush
Frank J Villani
Christopher Allan Teleha
Barry Fegely
Original Assignee
Furiex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339569(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Furiex Pharmaceuticals Inc filed Critical Furiex Pharmaceuticals Inc
Publication of MX339569B publication Critical patent/MX339569B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se relaciona a nuevos cristales de 5-({[2-amino-3-(4-carbamoil-2,6-dimetilfenil)-propionil]-[1-(4-fe nil-1h-imidazol-2-il4)-etil]-amino)}-metil)-2-ácido metoxibenzoico y los métodos para elaborar el zwitterion de 5-({[2-amino-3-(4-carbamoil-2,6-dimetilfenil)-propionil]-[1-(4-fe nil-1h-imidazol-2-il)-etiI]-amino}-metil)-2-ácido metoxibenzoico.
MX2010000323A 2007-07-09 2008-07-07 Nuevos cristales y procesos para elaborar 5-({[2-amino-3-(4-carbam oil-2,6-dimetilfenil)-propionil]-[1-(4-fenil-1h-imidazol-2-il)-et il]-amino}-metil)-2-acido metoxibenzoico. MX339569B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94858407P 2007-07-09 2007-07-09
PCT/US2008/069318 WO2009009480A2 (en) 2007-07-09 2008-07-07 Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid

Publications (1)

Publication Number Publication Date
MX339569B true MX339569B (es) 2016-05-31

Family

ID=39926468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000323A MX339569B (es) 2007-07-09 2008-07-07 Nuevos cristales y procesos para elaborar 5-({[2-amino-3-(4-carbam oil-2,6-dimetilfenil)-propionil]-[1-(4-fenil-1h-imidazol-2-il)-et il]-amino}-metil)-2-acido metoxibenzoico.

Country Status (25)

Country Link
US (7) US7994206B2 (es)
EP (1) EP2176234B1 (es)
JP (5) JP5702140B2 (es)
KR (2) KR101690161B1 (es)
CN (3) CN105111149A (es)
AU (1) AU2008275270C1 (es)
BR (1) BRPI0813632A2 (es)
CA (1) CA2695126C (es)
CO (1) CO6260079A2 (es)
CR (1) CR11260A (es)
EA (1) EA020024B1 (es)
EC (1) ECSP109863A (es)
ES (1) ES2567077T3 (es)
HK (1) HK1141519A1 (es)
HU (2) HUE028538T2 (es)
IL (1) IL203081A (es)
MX (1) MX339569B (es)
MY (1) MY174681A (es)
NI (1) NI201000001A (es)
NZ (1) NZ582420A (es)
PH (1) PH12016502561A1 (es)
SG (1) SG185941A1 (es)
UA (1) UA104713C2 (es)
WO (1) WO2009009480A2 (es)
ZA (1) ZA201000921B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7412462B2 (en) 2000-02-18 2008-08-12 Burnside Acquisition, Llc Data repository and method for promoting network storage of data
WO2009009480A2 (en) 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018069770A1 (en) * 2016-10-14 2018-04-19 Allergan Holdings Unlimited Company Methods of treatment using eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018198101A2 (en) * 2017-04-25 2018-11-01 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline form of eluxadoline
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
CA3018321A1 (en) 2017-09-25 2019-03-25 Apotex Inc. Novel crystalline form of eluxadoline
US10298921B1 (en) * 2018-02-27 2019-05-21 Looking Glass Factory, Inc. Superstereoscopic display with enhanced off-angle separation
US20210251964A1 (en) 2018-08-20 2021-08-19 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2021198780A1 (en) * 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003065441A (ja) 2001-08-28 2003-03-05 Japan Matekkusu Kk パッキン材料及びこの材料を用いたグランドパッキン
DK3112352T3 (en) 2004-03-15 2019-01-28 Janssen Pharmaceutica Nv OPIOID RECEPTOR MODULATORS
NZ590570A (en) 2005-03-14 2012-06-29 Janssen Pharmaceutica Nv Process for the preparation of opioid modulators
WO2009009480A2 (en) 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid

Also Published As

Publication number Publication date
US20150099724A1 (en) 2015-04-09
ES2567077T3 (es) 2016-04-19
US8859604B2 (en) 2014-10-14
AU2008275270B2 (en) 2013-10-10
KR101590596B1 (ko) 2016-02-01
EA020024B1 (ru) 2014-08-29
JP2016128433A (ja) 2016-07-14
CR11260A (es) 2013-01-25
AU2008275270C1 (en) 2014-04-17
JP2015129154A (ja) 2015-07-16
ECSP109863A (es) 2010-02-26
US20090018179A1 (en) 2009-01-15
EP2176234B1 (en) 2016-01-27
KR20100043210A (ko) 2010-04-28
IL203081A (en) 2016-09-29
MY174681A (en) 2020-05-07
US9789125B2 (en) 2017-10-17
HK1141519A1 (zh) 2010-11-12
CA2695126C (en) 2018-10-30
KR20150080006A (ko) 2015-07-08
ZA201000921B (en) 2011-04-28
CN105111149A (zh) 2015-12-02
NZ582420A (en) 2011-11-25
JP2010533191A (ja) 2010-10-21
JP6321690B2 (ja) 2018-05-09
US20160015724A1 (en) 2016-01-21
JP2014144946A (ja) 2014-08-14
US8691860B2 (en) 2014-04-08
US7994206B2 (en) 2011-08-09
UA104713C2 (ru) 2014-03-11
CN101730685A (zh) 2010-06-09
SG185941A1 (en) 2012-12-28
WO2009009480A2 (en) 2009-01-15
CA2695126A1 (en) 2009-01-15
BRPI0813632A2 (pt) 2014-12-23
JP2018123144A (ja) 2018-08-09
JP5870220B2 (ja) 2016-02-24
EA201070116A1 (ru) 2010-06-30
HUE028538T2 (en) 2016-12-28
US20140011851A1 (en) 2014-01-09
CO6260079A2 (es) 2011-03-22
US20140221444A1 (en) 2014-08-07
US9364489B2 (en) 2016-06-14
JP5702140B2 (ja) 2015-04-15
US9115091B2 (en) 2015-08-25
WO2009009480A3 (en) 2009-03-12
NI201000001A (es) 2010-07-22
CN111620823A (zh) 2020-09-04
KR101690161B1 (ko) 2016-12-27
US20110263868A1 (en) 2011-10-27
US20160354389A1 (en) 2016-12-08
PH12016502561A1 (en) 2017-09-04
JP5852625B2 (ja) 2016-02-03
AU2008275270A1 (en) 2009-01-15
US8609865B2 (en) 2013-12-17
HUS1700011I1 (hu) 2017-04-28
EP2176234A2 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
PH12016502561A1 (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
CR20110260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o un diurético
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
CL2007002949A1 (es) Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
MX2009007141A (es) Acidos 1-(3-piridinil)pirazol-4-il-aceticos sustituidos, procedimiento para su preparacion y su utilizacion como agentes herbicidas y reguladores del crecimiento de las plantas.
IL229395A0 (en) Adjusted release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-4)-5-n-methyl-h1 imidazol-1-yl)-3-(trifluoromethyl)phenyl] Benzamide is dissolved using organic acids
IL189375A0 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
WO2009064920A3 (en) Compounds and methods for modulating protein expression
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
HUE052128T2 (hu) Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
TW200732281A (en) Heterocyclic CETP inhibitors
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
PL382346A1 (pl) Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
MX365948B (es) Sintesis asimetrica de una pirrolidin-2-carboxamida sustituida.
EA201300719A3 (ru) Способ ферментативного синтеза (7s)-1-(3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил) n-метилметанамина, и применение в синтезе ивабрадина и его солей
MY161279A (en) Method for controlling weeds in paddy rice cultivation
CR11444A (es) Productos quimioterapeuticos cristalinos
WO2013120852A4 (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
UA102091C2 (ru) Способ получения сульфонилпиролов как ингибиторов hdac
CR11277A (es) Modificacion cristalina estable termodinamicamente de 2-(...2--cloro-4-(metilsufonil)-3-...(2,2,2-trifluoroetoxi)metil...carbonil)ciclohexano-1,3-diona.
PL402860A1 (pl) Sól amoniowa L-aminokwasu i sposób otrzymywania soli amoniowej L-aminokwasu
MX366213B (es) Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma.
EP2050738A4 (en) A NEW IMIDAZOLIDINONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR THE PRODUCTION OF AN OPTICALLY ACTIVE AMINO ACID
EP2192110A4 (en) PROCESS FOR PRODUCING AN OPTICALLY ACTIVE N- (HALOPROPYL) AMINO ACID DERIVATIVE

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FURIEX PHARMACEUTICALS, INC.

FG Grant or registration